Mengis Capital Management’s AbbVie ABBV Stock Holding History

Mengis Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2M	Hold	9,217	–	–	0.35%	75
2025 Q4	$2.11M	Buy	9,217 +34	+0.4%	+$7.75K	0.37%	70
2025 Q3	$2.13M	Hold	9,183	–	–	0.42%	65
2025 Q2	$1.7M	Hold	9,183	–	–	0.36%	72
2025 Q1	$1.92M	Sell	9,183 -40	-0.4%	-$7.78K	0.4%	65
2024 Q4	$1.64M	Buy	9,223 +200	+2%	+$36.8K	0.33%	78
2024 Q3	$1.78M	Buy	9,023 +115	+1%	+$21.5K	0.35%	76
2024 Q2	$1.53M	Sell	8,908 -200	-2%	-$33.1K	0.31%	82
2024 Q1	$1.66M	Buy	9,108 +200	+2%	+$34.5K	0.26%	80
2023 Q4	$1.38M	Hold	8,908	–	–	0.26%	78
2023 Q3	$1.33M	Buy	8,908 +1	+0%	+$147	0.28%	76
2023 Q2	$1.2M	Sell	8,907 -300	-3%	-$44K	0.24%	85
2023 Q1	$1.47M	Buy	9,207 +180	+2%	+$27.5K	0.31%	75
2022 Q4	$1.46M	Sell	9,027 -210	-2%	-$32.2K	0.32%	70
2022 Q3	$1.24M	Sell	9,237 -129	-1%	-$18.5K	0.29%	71
2022 Q2	$1.43M	Sell	9,366 -70	-0.7%	-$10.7K	0.32%	69
2022 Q1	$1.53M	Sell	9,436 -550	-6%	-$79.9K	0.29%	73
2021 Q4	$1.35M	Hold	9,986	–	–	0.25%	84
2021 Q3	$1.08M	Hold	9,986	–	–	0.23%	93
2021 Q2	$1.12M	Hold	9,986	–	–	0.23%	90
2021 Q1	$1.08M	Buy	9,986 +33	+0.3%	+$3.53K	0.24%	90
2020 Q4	$1.07M	Buy	9,953 +833	+9%	+$80K	0.26%	88
2020 Q3	$798K	Sell	9,120 -13	-0.1%	-$1.22K	0.22%	91
2020 Q2	$896K	Buy	9,133 +2,203	+32%	+$194K	0.27%	86
2020 Q1	$527K	Sell	6,930 -25	-0.4%	-$2.13K	0.18%	102
2019 Q4	$615K	Sell	6,955 -7,250	-51%	-$602K	0.17%	107
2019 Q3	$1.07M	Sell	14,205 -28,716	-67%	-$1.97M	0.32%	89
2019 Q2	$3.12M	Buy	42,921 +31,946	+291%	+$2.51M	0.95%	29
2019 Q1	$884K	Sell	10,975 -670	-6%	-$54.8K	0.49%	65
2018 Q4	$1.07M	Sell	11,645 -900	-7%	-$79.1K	0.68%	49
2018 Q3	$1.19M	Sell	12,545 -1,900	-13%	-$180K	0.65%	47
2018 Q2	$1.34M	Sell	14,445 -600	-4%	-$58.6K	0.79%	41
2018 Q1	$1.42M	Buy	15,045 +300	+2%	+$33K	0.85%	38
2017 Q4	$1.43M	Sell	14,745 -50	-0.3%	-$4.71K	0.86%	38
2017 Q3	$1.31M	Hold	14,795	–	–	0.88%	38
2017 Q2	$1.07M	Sell	14,795 -800	-5%	-$53.8K	0.76%	41
2017 Q1	$1.02M	Sell	15,595 -1,900	-11%	-$119K	0.74%	39
2016 Q4	$1.09M	Buy	17,495 +400	+2%	+$24.4K	0.87%	34
2016 Q3	$1.08M	Sell	17,095 -1,100	-6%	-$71.2K	0.9%	35
2016 Q2	$1.13M	Sell	18,195 -400	-2%	-$24.4K	0.99%	37
2016 Q1	$1.06M	Sell	18,595 -465	-2%	-$25.9K	0.98%	35
2015 Q4	$1.13M	Buy	19,060 +2,001	+12%	+$115K	0.98%	33
2015 Q3	$928K	Hold	17,059	–	–	0.86%	40
2015 Q2	$1.15M	Sell	17,059 -299	-2%	-$19.5K	0.96%	32
2015 Q1	$1.02M	Buy	17,358 +3,551	+26%	+$215K	0.89%	35
2014 Q4	$903K	Buy	+13,807	New	+$870K	0.87%	39

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mengis Capital Management's ABBV Position: Q1 2026 in Review

Mengis Capital Management held its AbbVie (ABBV) position steady in Q1 2026 at 9,217 shares worth $2M. The position accounts for 0.35% of the portfolio, ranked #75.

Mengis Capital Management first reported a position in ABBV in Q4 2014 and has held it in 46 quarters since. The position peaked at $3.12M in Q2 2019. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Mengis Capital Management held 9,217 shares of AbbVie worth $2M as of Q1 2026.
Mengis Capital Management left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.35% of Mengis Capital Management's portfolio in Q1 2026, its #75 holding.
Mengis Capital Management first reported a position in AbbVie in Q4 2014 and has held it in 46 quarters since.
Mengis Capital Management's AbbVie position peaked at $3.12M in Q2 2019.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Mengis Capital Management's 13F filing for Q1 2026, filed 12 May 2026.